Accepts insurance
Listing updated Oct 2, 2026
Aspen Clinic Harvey
Aspen Clinic Harvey · 1950 Manhattan Boulevard · Harvey, LA 70058
4.9· 265 Google reviews
Listing updated October 2, 2026
Retatrutide outlook for this practice
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
About this practice
Aspen Clinic Harvey is a weight-loss clinic in Harvey, Louisiana that offers telehealth. Its Google profile shows 265 reviews averaging 4.9 stars, reaching back to 2019, with 15 in the past year; the staff is mentioned most, in 52 reviews, followed by the team's knowledge, and 9 reviews mention results. According to the Aspen Clinic website, the program includes non-medical options such as nutrition education and personalized diet plans, vitamin injections, and an online supplement store.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Yes |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
★ 4.9
Google rating · 265 reviews
15
reviews in the past year (avg ★ 4.7)
2
reviews mention GLP-1 medications
12
reviews mention weight loss
Counts computed by RetaMaps from public Google reviews; most recent review 2026-04-04. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★4.9 across 265 Google reviews. Of the 100 reviews we analyzed, 98 (98%) are positive (4–5★) and 2 (2%) are negative (1–2★).
What patients like
- Friendly, helpful staff52 reviews
- Knowledgeable, professional providers22 reviews
- Weight-loss results9 reviews
- Feeling listened to6 reviews
Common complaints
Very few complaints — only 2 negative reviews, with no recurring theme.
5★
98
4★
0
3★
0
2★
0
1★
2
Most recent Google reviews
Corey B.★★★★★2026-04-04Everyone is super nice and as soon as you walk in their energy is unmatched! But I want to personally point out Mrs Shontae. The way she breaks down everything is amazing. She literally hits it on the nail. She makes you super comfortable to talk to her and her energy is amazing. Always smiling and always answering every single question and doubt that I have. She’s Legit!
Rhiannon C.★★★★★2026-03-27Love Aspen of Harvey! Everyone is always so nice!
Brandi B.★★★★★2026-02-21I love the staff , they are so helpful and friendly! I am so happy with my results since starting going to the aspen clinic and would definitely recommend to friends and family
Gerard A.★★★★★2026-01-08Great atmosphere, customer service is absolutely amazing! Shontae is very knowledgeable, explains everything in detail and wants to see you do great. I’ve been to a couple clinics and this one is by far the best I’ve ever been to! Highly recommend 10/5!!!!!
Ronaele C.★★★★★2025-12-30The staff is excellent and supportive. I tried the trizepitide and had a significant loss of appetite. I am encouraged by the staff to exercise n drink Water!! It definitely helps in the right way to lose weight. Eat right and exercise!! I’m
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Nearby providers in Harvey
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs